Name | Number of supported studies | Average coverage | |
---|---|---|---|
endothelial cell | 27 studies | 27% ± 11% | |
endothelial cell of lymphatic vessel | 22 studies | 41% ± 16% | |
fibroblast | 20 studies | 31% ± 10% | |
astrocyte | 14 studies | 37% ± 19% | |
myofibroblast cell | 8 studies | 25% ± 8% | |
endothelial cell of artery | 8 studies | 25% ± 8% | |
vein endothelial cell | 7 studies | 31% ± 20% | |
pericyte | 7 studies | 22% ± 6% | |
adipocyte | 6 studies | 28% ± 8% | |
oligodendrocyte precursor cell | 5 studies | 28% ± 10% | |
smooth muscle cell | 5 studies | 27% ± 7% | |
mesothelial cell | 4 studies | 36% ± 19% | |
endothelial cell of vascular tree | 4 studies | 31% ± 17% | |
connective tissue cell | 3 studies | 24% ± 4% | |
ependymal cell | 3 studies | 34% ± 21% | |
adventitial cell | 3 studies | 27% ± 5% | |
Schwann cell | 3 studies | 37% ± 20% |
Insufficient scRNA-seq data for expression of PLSCR4 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
lung | 100% | 4733.63 | 577 / 578 | 94% | 17.35 | 1088 / 1155 |
ovary | 100% | 4201.03 | 180 / 180 | 94% | 18.74 | 403 / 430 |
breast | 100% | 5965.68 | 459 / 459 | 93% | 17.93 | 1042 / 1118 |
thymus | 99% | 4587.31 | 649 / 653 | 93% | 18.09 | 563 / 605 |
intestine | 98% | 3173.56 | 945 / 966 | 89% | 13.02 | 469 / 527 |
brain | 86% | 1814.25 | 2278 / 2642 | 99% | 43.17 | 695 / 705 |
adrenal gland | 100% | 4716.26 | 258 / 258 | 84% | 16.24 | 193 / 230 |
esophagus | 90% | 2758.63 | 1295 / 1445 | 93% | 18.92 | 170 / 183 |
uterus | 99% | 4505.47 | 169 / 170 | 82% | 15.48 | 375 / 459 |
liver | 98% | 2418.78 | 222 / 226 | 83% | 12.53 | 335 / 406 |
kidney | 93% | 1742.66 | 83 / 89 | 85% | 24.47 | 768 / 901 |
prostate | 93% | 1922.04 | 227 / 245 | 82% | 9.07 | 410 / 502 |
pancreas | 77% | 1052.16 | 251 / 328 | 95% | 26.08 | 169 / 178 |
bladder | 100% | 2627.38 | 21 / 21 | 66% | 7.60 | 333 / 504 |
skin | 91% | 2363.33 | 1644 / 1809 | 75% | 13.41 | 353 / 472 |
stomach | 53% | 1543.18 | 190 / 359 | 85% | 13.35 | 243 / 286 |
adipose | 100% | 7991.09 | 1204 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 7116.04 | 1335 / 1335 | 0% | 0 | 0 / 0 |
spleen | 96% | 2191.86 | 231 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 87% | 15.89 | 39 / 45 |
heart | 78% | 1879.75 | 672 / 861 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 30% | 2.50 | 24 / 80 |
muscle | 21% | 276.21 | 169 / 803 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 10% | 0.53 | 3 / 29 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
peripheral blood | 0% | 0 | 0 / 929 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0071222 | Biological process | cellular response to lipopolysaccharide |
GO_0017121 | Biological process | plasma membrane phospholipid scrambling |
GO_0005886 | Cellular component | plasma membrane |
GO_0019899 | Molecular function | enzyme binding |
GO_0042609 | Molecular function | CD4 receptor binding |
GO_0005509 | Molecular function | calcium ion binding |
GO_0005515 | Molecular function | protein binding |
GO_0017124 | Molecular function | SH3 domain binding |
GO_0017128 | Molecular function | phospholipid scramblase activity |
Gene name | PLSCR4 |
Protein name | Phospholipid scramblase 4 (PL scramblase 4) (Ca(2+)-dependent phospholipid scramblase 4) (Cell growth-inhibiting gene 43 protein) (TRA1) Phospholipid scramblase Phospholipid scramblase 4 |
Synonyms | GIG43 |
Description | FUNCTION: May mediate accelerated ATP-independent bidirectional transbilayer migration of phospholipids upon binding calcium ions that results in a loss of phospholipid asymmetry in the plasma membrane. May play a central role in the initiation of fibrin clot formation, in the activation of mast cells and in the recognition of apoptotic and injured cells by the reticuloendothelial system. FUNCTION: May mediate accelerated ATP-independent bidirectional transbilayer migration of phospholipids upon binding calcium ions that results in a loss of phospholipid asymmetry in the plasma membrane. . FUNCTION: May mediate accelerated ATP-independent bidirectional transbilayer migration of phospholipids upon binding calcium ions that results in a loss of phospholipid asymmetry in the plasma membrane. . FUNCTION: May mediate accelerated ATP-independent bidirectional transbilayer migration of phospholipids upon binding calcium ions that results in a loss of phospholipid asymmetry in the plasma membrane. . FUNCTION: May mediate accelerated ATP-independent bidirectional transbilayer migration of phospholipids upon binding calcium ions that results in a loss of phospholipid asymmetry in the plasma membrane. . |
Accessions | C9J664 E9PHR9 C9J3P9 ENST00000481701.5 ENST00000460350.5 C9JNW2 C9J916 ENST00000446574.6 [Q9NRQ2-1] ENST00000493382.5 [Q9NRQ2-1] ENST00000476202.5 ENST00000354952.7 [Q9NRQ2-1] ENST00000433593.6 [Q9NRQ2-2] Q9NRQ2 ENST00000498625.1 ENST00000460885.5 C9J6E1 ENST00000383083.6 |